When a new anti-seizure medication is developed, and where there is long-term clinical research supporting its use, Epilepsy Ireland will advocate that the medication be reimbursed in Ireland – meaning it is available free of charge on both the Long-Term Illness and Medical Card schemes.
Why?
Epilepsy is an incredibly individual condition and due to the individual nature of the condition, it can often be a journey in finding the right treatment course for a person’s individual epilepsy. Up to 70% of people living with epilepsy can become seizure free if the right treatment for their epilepsy is identified.
The more options that are available to clinicians to potentially treat their patients, the better – but it is equally important that patients can access new medications – particularly when they have proven clinical research around their potential positive impact for patients. Access to more proven medications, may help a person become seizure free or significantly improve their quality of life – this is why it is important that they are approved for reimbursement.
What do we do?
We closely monitor global developments around emerging treatments and track when pharmaceutical companies bring forward new medications for regulatory approval in Europe and other jurisdictions. We will liaise with regulatory authorities and pharmaceutical companies alike, encouraging them to bring forward applications for patients in Ireland without delay.
When applications for reimbursement are brought forward in Ireland, and where there is long-term clinical evidence supporting a medication’s use in epilepsy, we will make a supportive submission to the National Centre for Pharmacoeconomics supporting reimbursement.
Progress to date
To date Epilepsy Ireland have successfully advocated for the reimbursement of Epidyolex and Cenobamate – the two most recent new medications to be developed and to have sought reimbursement in Ireland in recent years.
We also made submissions supporting the reimbursement of FINTEPLA in 2024.
Latest News
The below are some of the latest updates in relation to the reimbursement of new medications and associated articles in the news section of our website where you can read more.
- November 2024 - Fenfluramine (FINTEPLA®) approved for reimbursement for patients living with Dravet and LGS
- September 2024 - Epilepsy Ireland make submission supporting reimbursement of FINTEPLA for Lennox Gastaut Syndrome
- August 2024 - Epilepsy Ireland make submission supporting reimbursement of FINTEPLA for Dravet Syndrome
- June 2024 - Reimbursement submission for new medication for Dravet Syndrome & Lennox Gastaut Syndrome – we need your help!
- May 2023 - Cenobamate (Ontozry®) approved for reimbursement
- October 2022 - NCPE issue positive recommendation on reimbursement of Cenobamate (Ontozry®)
- July 2022 - ONTOZRY® Update - Epilepsy Ireland make submission to NCPE supporting reimbursement of the drug
- June 2022 - Can you help support reimbursement for a new Anti-epileptic drug?
- December 2021 - NICE issues positive recommendation on use of new epilepsy drug in the UK
- December 2021 - HSE approve Reimbursement of CBD Medication Epidyolex
- September 2021 - New research reports positive outcomes for patients with Dravet Syndrome treated with FINTEPLA
- April 2021 - Study on Epidyolex use in treatment resistant epilepsy reports positive findings.
- April 2021 - ONTOZRY® granted marketing authorisation by European Commission
- March 2021 - Epidyolex Update
- February 2021 - FINTEPLA (Fenfluramine) approved by EU Commission for use in Dravet Syndrome
- October 2020 - Epidyolex Update - Epilepsy Ireland make submission to NCPE supporting reimbursement of the drug
- December 2019 - New study finds that Epidyolex has positive impact on seizure frequency in TSC
- November 2019 - Epidyolex approved by NICE for reimbursement in UK
- September 2019 - Epidyolex receives marketing approval by European Commission
- August 2019 - Epidyolex turned down for NHS reimbursement
- August 2019 - CBD-based drug moves closer to authorisation in Europe